BioLight Life Sciences Past Earnings Performance
Past criteria checks 0/6
BioLight Life Sciences's earnings have been declining at an average annual rate of -68.1%, while the Life Sciences industry saw earnings growing at 21.9% annually. Revenues have been declining at an average rate of 81.4% per year.
Key information
-68.1%
Earnings growth rate
-68.6%
EPS growth rate
| Life Sciences Industry Growth | 26.8% |
| Revenue growth rate | -81.4% |
| Return on equity | -90.7% |
| Net Margin | -22,050.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How BioLight Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 0 | -26 | 6 | 5 |
| 30 Sep 23 | 0 | -28 | 7 | 4 |
| 30 Jun 23 | 0 | -29 | 7 | 4 |
| 31 Mar 23 | 0 | -10 | 7 | 4 |
| 31 Dec 22 | 0 | -8 | 7 | 4 |
| 30 Sep 22 | 0 | -7 | 7 | 4 |
| 30 Jun 22 | 0 | -5 | 7 | 4 |
| 31 Mar 22 | 0 | -3 | 7 | 4 |
| 31 Dec 21 | 0 | 0 | 6 | 4 |
| 30 Sep 21 | 0 | 0 | 6 | 4 |
| 30 Jun 21 | 0 | -1 | 7 | 4 |
| 31 Mar 21 | 0 | -8 | 6 | 4 |
| 31 Dec 20 | 0 | -12 | 7 | 4 |
| 30 Sep 20 | 0 | -8 | 4 | 3 |
| 30 Jun 20 | 0 | -8 | 5 | 4 |
| 31 Mar 20 | 0 | -9 | 9 | 6 |
| 31 Dec 19 | 0 | -12 | 6 | 5 |
| 30 Sep 19 | 0 | -13 | 10 | 7 |
| 30 Jun 19 | 0 | 64 | 11 | 8 |
| 31 Mar 19 | 3 | 64 | 13 | 9 |
| 31 Dec 18 | 3 | 70 | 11 | 8 |
| 30 Sep 18 | 4 | 65 | 14 | 10 |
| 30 Jun 18 | 4 | -14 | 13 | 12 |
| 31 Mar 18 | 1 | -16 | 13 | 14 |
| 31 Dec 17 | 1 | -17 | 13 | 15 |
| 30 Sep 17 | 1 | -21 | 13 | 15 |
| 30 Jun 17 | 2 | -19 | 13 | 13 |
| 31 Mar 17 | 2 | -18 | 13 | 12 |
| 31 Dec 16 | 2 | -22 | 14 | 11 |
| 30 Sep 16 | 2 | -21 | 14 | 11 |
| 30 Jun 16 | 2 | -21 | 14 | 11 |
| 31 Mar 16 | 2 | -23 | 14 | 13 |
| 31 Dec 15 | 1 | -19 | 13 | 13 |
| 30 Sep 15 | 2 | -20 | 13 | 15 |
| 30 Jun 15 | 1 | -22 | 13 | 16 |
| 31 Mar 15 | 1 | -22 | 12 | 17 |
| 31 Dec 14 | 1 | -23 | 12 | 19 |
| 30 Sep 14 | 0 | -22 | 12 | 18 |
| 30 Jun 14 | 0 | -21 | 11 | 18 |
| 31 Mar 14 | 0 | -20 | 11 | 19 |
| 31 Dec 13 | 0 | -19 | 10 | 18 |
| 30 Sep 13 | 0 | -17 | 11 | 17 |
| 30 Jun 13 | 0 | -17 | 11 | 21 |
Quality Earnings: BOLT is currently unprofitable.
Growing Profit Margin: BOLT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BOLT is unprofitable, and losses have increased over the past 5 years at a rate of 68.1% per year.
Accelerating Growth: Unable to compare BOLT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BOLT is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (0.4%).
Return on Equity
High ROE: BOLT has a negative Return on Equity (-90.71%), as it is currently unprofitable.